LifeMD (NASDAQ:LFMD) Price Target Lowered to $6.00 at Mizuho

LifeMD (NASDAQ:LFMD - Get Free Report) had its price objective decreased by analysts at Mizuho from $8.00 to $6.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a "neutral" rating on the stock. Mizuho's price objective would suggest a potential upside of 50.00% from the company's previous close.

• Can the New CEO Revive This Struggling Telehealth Stock?

A number of other research firms have also commented on LFMD. Wall Street Zen lowered shares of LifeMD from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Zacks Research raised LifeMD from a "strong sell" rating to a "hold" rating in a report on Friday, September 5th. KeyCorp reduced their price objective on LifeMD from $14.00 to $12.00 and set an "overweight" rating for the company in a research note on Wednesday, August 6th. Lake Street Capital decreased their price objective on LifeMD from $14.00 to $8.00 and set a "buy" rating for the company in a research report on Tuesday. Finally, BTIG Research dropped their target price on LifeMD from $18.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $10.57.

Get Our Latest Analysis on LifeMD

LifeMD Trading Down 2.2%

• Hims & Hers Health Soars on Generic GLP-1 Rollout Plans

LFMD opened at $4.00 on Wednesday. The company has a quick ratio of 0.72, a current ratio of 0.77 and a debt-to-equity ratio of 9.21. LifeMD has a 52 week low of $3.43 and a 52 week high of $15.84. The business's 50 day moving average is $6.01 and its two-hundred day moving average is $8.68. The firm has a market cap of $189.67 million, a price-to-earnings ratio of -23.54 and a beta of 1.57.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings data on Monday, November 17th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The firm had revenue of $60.17 million during the quarter, compared to analyst estimates of $62.07 million. During the same period in the prior year, the firm earned $0.09 earnings per share. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, research analysts predict that LifeMD will post -0.56 EPS for the current year.

Insiders Place Their Bets

• LifeMD Can Surge on Its GLP-1 Offerings

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of the business's stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total transaction of $444,000.00. Following the transaction, the insider owned 605,000 shares in the company, valued at approximately $3,581,600. The trade was a 11.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 18.40% of the company's stock.

Institutional Trading of LifeMD

Institutional investors have recently modified their holdings of the business. Arrowstreet Capital Limited Partnership lifted its holdings in LifeMD by 1,767.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company's stock valued at $5,924,000 after acquiring an additional 411,651 shares during the period. JPMorgan Chase & Co. grew its stake in shares of LifeMD by 581.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company's stock worth $5,619,000 after purchasing an additional 352,004 shares during the period. Jump Financial LLC increased its holdings in shares of LifeMD by 205.0% in the 2nd quarter. Jump Financial LLC now owns 515,052 shares of the company's stock valued at $7,015,000 after purchasing an additional 346,171 shares in the last quarter. Invesco Ltd. lifted its stake in shares of LifeMD by 1,904.0% in the second quarter. Invesco Ltd. now owns 327,080 shares of the company's stock valued at $4,455,000 after purchasing an additional 310,759 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of LifeMD in the first quarter valued at about $1,545,000. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

Featured Articles

• Five stocks we like better than LifeMD
• What is a Stock Market Index and How Do You Use Them?
• Buyer Beware: Carvana Is Driving an Auto Lending Crisis
• What is Insider Trading? What You Can Learn from Insider Trading
• Healthcare Rotation Underway: 3 Stocks Leading the Charge
• What Are Dividend Challengers?
• Medtronic Stock Finds Its Footing—Now It’s Gaining Momentum

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in LifeMD Right Now?

Before you consider LifeMD, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.

While LifeMD currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here